Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rebus Holdings, Inc. (NSPXD)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0952+0.0002 (+0.21%)
At close: 11:57AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0950
Open0.0985
BidN/A x N/A
AskN/A x N/A
Day's Range0.0900 - 0.1089
52 Week Range0.0750 - 4.2751
Volume27,345
Avg. Volume223,964
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline

    * Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist * Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces the sale of $500,000 of a senior convertible debenture ("Debenture") from an existing institutional investor to pursue the research and development of the company's novel portfolio of adenosine receptor antagonists and for general corporate purposes.

  • ACCESSWIRE

    Inspyr Therapeutics Strengthens Global Intellectual Property

    * Expansion of patent portfolio of novel adenosine immuno-modulator compoundsWESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc.

Advertisement
Advertisement